Studies of external validation: PROCAM Assmann 1990146)

Validation study IDValidating population, location, date, description Follow upPopulation characteristics
Inclusion
Exclusion
Co-morbidity
Changes to methods.
Methods used for validation
Results
Attempt at recalibration
Authors conclusions: applicability in studied population.
Reviewer notes
Assmann 1990146Helsinki Heart Study

RCT of antihypertensive therapy (Gemfibrozil)
Age 40–55
N=2051 gemfibrozil
N=2030 control
Assymptomatic Primary dyslipidaemia (non-HDL cholesterol > 5.2mmol/L)
CHD events

Calibration: predicted: observed
CalibrationPROCAM study model predicted outcome in both treatment groups. Numbers and P:O ratio based on Frick et al. 1987307
P:O
Gemfibrozil group1.09
Control group0.98

From: Appendix 6, Studies of external validation of risk-scoring methods (part complete)

Cover of A Systematic Review of Risk Scoring Methods and Clinical Decision Aids Used in the Primary Prevention of Coronary Heart Disease (Supplement)
A Systematic Review of Risk Scoring Methods and Clinical Decision Aids Used in the Primary Prevention of Coronary Heart Disease (Supplement) [Internet].
NICE Clinical Guidelines, No. 67S.
Beswick AD, Brindle P, Fahey T, et al.
Copyright © 2008, Royal College of General Practitioners.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.